Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosulpiride for Diabetic Retinopathy and Macular Edema
NCT03161652Phase 2Recruiting
- Start
- May 2017
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of levosulpiride in diabetic retinopathy (DR) and diabetic macular edema (DME) (8 arms). Primary endpoints: Visual Acuity at 24 weeks, Retinal Thickness at 24 weeks and 5 more. Started May 2017; status: recruiting.
02
Drugs
levosulpiride
03
Conditions
diabetic retinopathy (DR)diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03161652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03161652.